Retinitis Pigmentosa (RP) Clinical Trial
Official title:
A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)
This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa. Four different dose levels of cells will be assessed in each of two groups of patients.
The primary purpose of this study is to test the safety and tolerability of the
administration of a single dose of jCell to adults with retinitis pigmentosa.
The goal of jCell therapy is to preserve vision by intervening in the disease at a time when
host photoreceptors can be protected and potentially reactivated.
Human allogeneic retinal progenitor cells will be injected into adults with advanced RP to
see if the procedure is safe, if the cells survive, and whether they have any impact on the
visual status of the patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03975543 -
Retrospective Natural History Study of Retinitis Pigmentosa
|
||
| Recruiting |
NCT04763369 -
Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
|
Phase 2 | |
| Completed |
NCT01543906 -
Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)
|
Phase 1 | |
| Completed |
NCT02575430 -
Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT
|
N/A |